Technical Analysis for CERS - Cerus Corporation

Grade Last Price % Change Price Change
grade D 5.39 -1.46% -0.08
CERS closed down 1.46 percent on Monday, May 20, 2019, on 66 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CERS trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Narrow Range Bar Range Contraction -1.46%
NR7 Range Contraction -1.46%
Calm After Storm Range Contraction -1.82%
Inside Day Range Contraction -1.82%
Calm After Storm Range Contraction -2.53%
Calm After Storm Range Contraction -1.28%
Lower Bollinger Band Walk Weakness -1.28%
New Downtrend Bearish -1.64%
Calm After Storm Range Contraction -1.64%

Older signals for CERS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Anatomy Blood Transfusion Medicine Hematology Blood Products Coagulation System Blood Transfusion Platelet Red Blood Cell
Is CERS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.05
52 Week Low 4.705
Average Volume 787,794
200-Day Moving Average 6.2228
50-Day Moving Average 6.104
20-Day Moving Average 5.885
10-Day Moving Average 5.616
Average True Range 0.2688
ADX 27.86
+DI 14.0143
-DI 28.1403
Chandelier Exit (Long, 3 ATRs ) 5.8036
Chandelier Exit (Short, 3 ATRs ) 5.9464
Upper Bollinger Band 6.6281
Lower Bollinger Band 5.1419
Percent B (%b) 0.17
BandWidth 25.254036
MACD Line -0.2056
MACD Signal Line -0.1486
MACD Histogram -0.0569
Fundamentals Value
Market Cap 588.24 Million
Num Shares 109 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -8.84
Price-to-Sales 8.39
Price-to-Book 7.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.63
Resistance 3 (R3) 5.65 5.60 5.59
Resistance 2 (R2) 5.60 5.54 5.59 5.58
Resistance 1 (R1) 5.49 5.50 5.47 5.47 5.56
Pivot Point 5.44 5.44 5.42 5.43 5.44
Support 1 (S1) 5.33 5.38 5.31 5.31 5.22
Support 2 (S2) 5.28 5.34 5.27 5.20
Support 3 (S3) 5.17 5.28 5.19
Support 4 (S4) 5.15